D.
C.-based Vanda Pharmaceuticals Inc. has expanded its portfolio to include research and development into treatments for cystic fibrosis and blood cancer.
During a first-quarter earnings call this week,CEO Mihael Polymeropoulos said Vanda (NASDAQ: VNDA) is on track to file an investigational current drug application for trichostatin A to the Food and Drug Administration in mid-2017 for clinical study of hematologic malignancies.
Meanwhile, in March, or Vanda agreed to pay up to $46 million to the University…
Source: bizjournals.com